It looked like a surefire way to make billions.
A year ago, two new drugs that used a novel mechanism to drive down cholesterol levels came on the market, and were promptly crowned as blockbusters in waiting. Analysts estimated sales at more than $3 billion a year.
But the two drugs have been commercial flops, in part due to a complicated reimbursement system that has frustrated doctors, confused patients, and left the biotech industry worried about the implications for other high-priced drugs in the pipeline.
“These launches so far are close to, if not the biggest, wastes of development and commercial investment in recent industry history,” said Geoffrey Porges, a biotech analyst at Leerink.
The companies behind the drugs — Amgen (AMGN) and the partnership of Sanofi (SNY) and Regeneron — are spending hundreds of millions to promote their products but have reaped a mere fraction of that in revenue. “You don’t need to be in finance to know that that’s not a sustainable business proposition,” Porges said.
No one disputes that the new drugs, Repatha and Praluent, are excellent at lowering bad cholesterol, or LDL. They often succeed where the traditional treatment — an inexpensive class of drugs called statins — fails. The problem boils down to doctors who are reluctant to write prescriptions, insurers who are unwilling to pay for them, and drug companies that have failed to understand a fast-changing marketplace.
The failures could send a chill through the still-booming biotech business, which relies on the idea that the risky, expensive process of developing new drugs can one day pay off big.
The new treatments work by blocking a protein called PCSK9, thereby freeing up the body to clear out LDL lingering in the blood. In clinical trials, PCSK9 blockers were able to slash LDL cholesterol by more than 50 percent, even when added to a maximum dose of statin drugs like Pfizer’s (PFE) Lipitor.
Cardiologists say the drugs could save lives. An estimated 15 percent of the roughly 74 million Americans with high cholesterol have alarmingly high LDL levels despite taking other drugs. Many would be candidates for the new treatments.
And yet the new therapies have only been prescribed about 120,000 times, according to data from QuintilesIMS, grossing just above $150 million combined in the past year.
Why aren’t they flying off the shelves?
For one, some doctors are hesitant to prescribe them until there’s more information said Dr. Pradeep Natarajan, a cardiologist at Massachusetts General Hospital.
Yes, the treatments lower cholesterol, but does that actually ward off heart attack and stroke? Long-term results on how PCSK9 blockers affect broader health and mortality won’t be available until next year.
Another hurdle: Getting insurers to pay for the drugs, which both have list prices of about $14,000 a year.
To secure coverage for a single patient, doctors must submit pages and pages of documentation to prove that patients have already tried at least two statin drugs to no avail, or that they have an inherited disorder that results in sky-high LDL levels. In some cases, the paperwork has more than 40 questions.
And insurers almost always say no.
Payers have denied more than 88 percent of first-time prescriptions for patients with commercial insurance in the past year, according to Symphony Health Solutions. For those on Medicare, the first-time rejection rate was about 77 percent.
And even after an average of five appeals, more than two-thirds of prescriptions still aren’t getting covered, according to Amgen.
“There’s absolutely frustration among my colleagues,” said Natarajan, who specializes in treating patients with particularly high cholesterol. “They’re writing prescriptions where they think [PCSK9 drugs] are indicated, and then payers are saying no.”
But the people doing the rejecting say they’re justified.
When PCSK9 drugs first won approval, doctors were writing prescriptions for patients who didn’t fall in the categories that the drug was approved to treat, according to Dr. Steve Miller, chief medical officer of Express Scripts. Companies like his are paid by insurers and employers to negotiate drug prices and determine which treatments get reimbursed.
PCSK9 therapies are expensive, and if the likes of Express Scripts don’t limit their use, it could cost society upward of $100 billion a year, Miller said.
That figure is “absurdly off-base,” responded Dr. Joshua Ofman, Amgen’s head of value and access. Payers cooked up a doomsday economic scenario to help negotiate rebates from drug manufacturers, Ofman said, and they’ve since instituted “a very onerous practice designed to keep patients from getting these drugs.”
If data that will roll out in the next few years prove that PCSK9 drugs save lives, both payers and drug makers expect them to be more widely used. Cardiologists say they’ll be quicker to write prescriptions if they can confidently say patients will be less likely to suffer heart attacks or strokes. And the price might even come down, as Pfizer expects to debut a PCSK9 inhibitor of its own next year, looking to steal market share from Amgen, Sanofi, and Regeneron.
But the squabble over cost, access, and availability is unlikely to end any time soon. And the fear among biotech insiders is that the commercial disappointment of PCSK9 therapies will imperil new cardiovascular therapies.
The Medicines Company (MDCO), a New Jersey biotech, is at work on a next-generation PCSK9 drug that could be dosed just twice a year instead of monthly or every two weeks. And Esperion Therapeutics (ESPR), headquartered in Michigan, is developing a pill that attacks LDL cholesterol through another mechanism.
While each is years away from approval, the companies have been operating under the assumption that their drugs will be profitable if they can simply show they reduce cholesterol. The uphill battle with first-generation PCSK9 treatments suggests otherwise.
“The interesting question is whether the industry will continue to invest — and whether investors will continue to support — further development of drugs for these metabolic targets where very large studies [of health effects] are required at tremendous cost, and where the commercial return is disappointing,” said Leerink’s Porges. “I think there’s going to be some reconsideration of that if this trend continues.”
And that could have a downstream effect on patient care, said Dr. Steven Nissen, a cardiologist at the Cleveland Clinic.
“If I were the CEO of a major pharmaceutical company, and I knew I could not recover the cost of developing an innovative medicine, I wouldn’t do it,” Nissen said at the Cleveland Clinic’s Medical Innovation Summit this week.
Stuck in the middle are physicians and patients, waiting on the industry to prove its drugs are effective and wading through payer bureaucracy to actually use them.
“Limiting access because of cost is reasonable from insurer’s perspective, but from the patients’ perspective, they should be getting these medicines,” said MGH’s Natarajan. “I don’t think we’ve achieved that balance yet.”